162 related articles for article (PubMed ID: 17396306)
1. Bevacizumab for non-small-cell lung cancer.
Sculier JP; Meert AP; Paesmans M
N Engl J Med; 2007 Mar; 356(13):1373-4; author reply 1374-5. PubMed ID: 17396306
[No Abstract] [Full Text] [Related]
2. Bevacizumab for non-small-cell lung cancer.
Garassino MC; Hollander L; Torri V
N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17392310
[No Abstract] [Full Text] [Related]
3. Bevacizumab for non-small-cell lung cancer.
Sonpavde G
N Engl J Med; 2007 Mar; 356(13):1374; author reply 1374-5. PubMed ID: 17396304
[No Abstract] [Full Text] [Related]
4. Bevacizumab for non-small-cell lung cancer.
Oxnard GR
N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17396305
[No Abstract] [Full Text] [Related]
5. Improved survival with addition of bevacizumab to paclitaxel and carboplatin in elderly patients with non-small-cell lung cancer.
Atkins CD
J Clin Oncol; 2008 Apr; 26(12):2063-4; author reply 2064-5. PubMed ID: 18421066
[No Abstract] [Full Text] [Related]
6. In focus: non-small cell lung cancer: E1505.
Clin Adv Hematol Oncol; 2007 Mar; 5(3):206-8. PubMed ID: 17519882
[No Abstract] [Full Text] [Related]
7. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
8. Reporting of subset analysis: where do we draw the line?
Goel S
J Clin Oncol; 2008 Apr; 26(12):2062-3; author reply 2064-5. PubMed ID: 18421065
[No Abstract] [Full Text] [Related]
9. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD; Bonomi P; Socinski MA; Govindan R; Hong S; Obasaju C; Pennella EJ; Girvan AC; Guba SC
Clin Lung Cancer; 2009 Jul; 10(4):252-6. PubMed ID: 19632943
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men?
Herbst RS
Clin Lung Cancer; 2008 Mar; 9(2):75-6. PubMed ID: 18501092
[No Abstract] [Full Text] [Related]
11. Anti-angiogenesis drugs in lung cancer.
Lee SM; Baas P; Wakelee H
Respirology; 2010 Apr; 15(3):387-92. PubMed ID: 20337999
[TBL] [Abstract][Full Text] [Related]
12. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.
Zinner RG; Saxman SB; Peng G; Monberg MJ; Ortuzar WI
Clin Lung Cancer; 2010 Sep; 11(5):352-7. PubMed ID: 20837462
[TBL] [Abstract][Full Text] [Related]
13. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
[TBL] [Abstract][Full Text] [Related]
14. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
15. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
Goulart B; Ramsey S
Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
[TBL] [Abstract][Full Text] [Related]
16. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
[TBL] [Abstract][Full Text] [Related]
17. [A case of complete resection of non-squamous non-small-cell lung cancer after induction chemotherapy using carboplatin, paclitaxel, and bevacizumab].
Kawaharada Y; Imai K; Minamiya Y; Saito H; Konno H; Fujishima S; Ogawa J
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1533-7. PubMed ID: 23064066
[TBL] [Abstract][Full Text] [Related]
18. Combination of standard chemotherapy and targeted agents.
Bareschino MA; Morgillo F; Ciardiello F
J Thorac Oncol; 2007 May; 2(5 Suppl):S19-23. PubMed ID: 17457224
[No Abstract] [Full Text] [Related]
19. Study shows 2-year survival advantage for docetaxel.
Expert Rev Anticancer Ther; 2001 Oct; 1(3):323-4. PubMed ID: 12113094
[No Abstract] [Full Text] [Related]
20. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Bunn PA
Semin Oncol; 1996 Dec; 23(6 Suppl 16):18-25. PubMed ID: 9007116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
